SCHEMBL2403697

SCHEMBL2403697

COc1ccc(S(=O)(=O)Nc2cccc3cc[nH]c23)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TUBB4A P04350 1/20 0.61
TUBB P07437 1/20 0.61
TUBA3C P0DPH7 1/20 0.61
TUBA1B P68363 1/20 0.61
TUBA4A P68366 1/20 0.61
TUBB4B P68371 1/20 0.61
TUBB3 Q13509 1/20 0.61
TUBB2A Q13885 1/20 0.61
TUBB8 Q3ZCM7 1/20 0.61
TUBA3E Q6PEY2 1/20 0.61
TUBA1A Q71U36 1/20 0.61
TUBA1C Q9BQE3 1/20 0.61
TUBB6 Q9BUF5 1/20 0.61
TUBB2B Q9BVA1 1/20 0.61
TUBB1 Q9H4B7 1/20 0.61
NR3C1 P04150 1/20 0.59
PGR P06401 1/20 0.59
NR3C2 P08235 1/20 0.59
AR P10275 1/20 0.59
GLO1 Q04760 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2367682 0.85 NR3C1 (0.64) NR3C1PGRNR3C2ARSLC40A1
SCHEMBL2367383 0.83 NR3C1 (0.65) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL1984869 0.82 CA1 (0.60) NR3C1PGRNR3C2ARKMT2A
SCHEMBL2367735 0.82 NR3C1 (0.60) NR3C1PGRNR3C2ARSLC40A1
SCHEMBL3061467 0.80 GLO1 (0.59) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL3982737 0.79 ESR1 (0.53) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL2367583 0.79 NFKBIA (0.58) NR3C1PGRNR3C2ARKMT2A
SCHEMBL3061760 0.79 NR3C1 (0.56) NR3C1PGRNR3C2ARKEAP1
SCHEMBL3073814 0.79 NR3C1 (0.56) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL3061022 0.79 GLO1 (0.58) NR3C1PGRNR3C2ARGLO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2366687-B1 Benzenesulfonamide derivatives and pharmaceutical composition thereof PURZER PHARMACEUTICAL CO LTD (CN) 2015-11-04 EP disclosed
US-8173693-B2 Benzenesulfonamide derivatives and pharmaceutical composition thereof PURZER PHARMACEUTICAL CO., LTD. (TW) 2012-05-08 US disclosed
US-8173693-B2 Benzenesulfonamide derivatives and pharmaceutical composition thereof PURZER PHARMACEUTICAL CO., LTD. (TW) 2012-05-08 US disclosed
CN-102199148-A Benzenesulfonamide derivatives and pharmaceutical compositions thereof PURZER PHARMACEUTICAL CO LTD 2011-09-28 CN disclosed
US-20110230651-A1 Benzenesulfonamide derivatives and pharmaceutical composition therof PURZER PHARMACEUTICAL CO., LTD. (TW) 2011-09-22 US disclosed
US-20110230651-A1 Benzenesulfonamide derivatives and pharmaceutical composition therof PURZER PHARMACEUTICAL CO., LTD. (TW) 2011-09-22 US disclosed
EP-1433479-B1 APPETITE-STIMULATING AGENTS AND REMEDIES FOR ANOREXIA EISAI R&D MAN CO LTD (JP) 2007-12-05 EP disclosed
US-7015241-B2 Appetite-stimulating agents and remedies for anorexia EISAI CO., LTD. (JP) 2006-03-21 US disclosed
US-20040242628-A1 Appetite-stimulating agents and remedies for anorexia EISAI R&D MANAGEMENT CO., LTD. (JP) 2004-12-02 US disclosed
US-20040235866-A1 Lymphocytic activation inhibitor and remedial agent for autoimmune disease EISAI R&D MANAGEMENT CO., LTD. (JP) 2004-11-25 US disclosed
EP-1433479-A1 APPETITE-STIMULATING AGENTS AND REMEDIES FOR ANOREXIA Eisai Co., Ltd (JP) 2004-06-30 EP disclosed
EP-1430894-A1 LYMPHOCYTIC ACTIVATION INHIBITOR AND REMEDIAL AGENT FOR AUTOIMMUNE DISEASE Eisai Co. Ltd (JP) 2004-06-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040235866-A1 Lymphocytic activation inhibitor and remedial agent for autoimmune disease NFATC1, CHUK, CD4 TUBB4A 3830/4885TUBB 3357/4885TUBA3C 4494/4885
US-20040242628-A1 Appetite-stimulating agents and remedies for anorexia GHSR, CCKAR, SUCNR1 TUBB4A 3574/4885TUBB 3163/4885TUBA3C 3865/4885
US-20110230651-A1 Benzenesulfonamide derivatives and pharmaceutical composition therof CCNI, CCNE1, CCND1 TUBB4A 2433/4885TUBB 2353/4885TUBA3C 2851/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.